<DOC>
	<DOCNO>NCT00088621</DOCNO>
	<brief_summary>A 1-year outpatient study test safety tolerability new medication treatment schizophrenia</brief_summary>
	<brief_title>A Study Test Safety Tolerability New Medication Treatment Schizophrenia</brief_title>
	<detailed_description>Study evaluate long-term safety tolerability new compound treatment patient schizophrenia assessed adverse event ( AEs ) , measure extra pyramidal symptom ( EPS ; Abnormal Involuntary Movement Scale [ AIMS ] , Barnes Akathisia Scale [ BAS ] , Simpson-Angus Rating Scale [ SAS ] ) , vital sign measurement , electrocardiogram ( ECGs ) , clinical laboratory evaluation .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Patients must participate study D1050196 ( A Study Test Effectiveness Safety New Medication Treatment Schizophrenia ) either : Successfully complete OR Patients must discontinue minimum 2 week treatment due lack efficacy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Latuda</keyword>
	<keyword>Lurasidone</keyword>
</DOC>